Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction

Overview

The objective of this project is the non-invasive prenatal detection of placenta-limited aneuploidies, in patients whose fetuses have a intrauterine growth restriction below 3rd percentile, in parallel with an amniocentesis. This study will allow the chromosomal study of the placenta in pregnant women whose genetic prenatal diagnosis, made by amniocentesis, does not allow exploring the placental causes of fetal RCIU.

Full Title of Study: “Non-invasive Prenatal Testing of Placental Chromosomal Abnormalities in Fetus With Intrauterine Growth Restriction”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 5, 2024

Detailed Description

Placental chromosomal aneuploidies will be detected by high-throughput whole genome sequencing of non-cellular DNA present in maternal plasma during pregnancy. The study of the cfDNA will be carried out from a blood sample with the automated solution VERISEQ NIPT (Illumina) using the software illumina VeriSeq v2, allowing the detection of all chromosomal abnormalities.

Interventions

  • Biological: Blood samples
    • Performed a 10 ml blood sample in each of the 200 patients included.

Arms, Groups and Cohorts

  • Patient having a fetus with intra-uterine growth restriction diagnosis below the 3rd percentile

Clinical Trial Outcome Measures

Primary Measures

  • Determine the presence or absence of chromosomal abnormality in the plasma sample. studied.
    • Time Frame: Inclusion date
    • The result will be expressed in presence or absence of chromosomal abnormality such as trisomy, monosomy, deletion or duplication. The result will be compared with the fetal chromosome analysis carried out concomitantly on liquid amniotic as part of the treatment: if the analysis on Liquid Amniotic shows the same anomaly, it means that it is a fetal abnormality, if the Liquid Amniotic test is normal, it means that it is most likely an abnormality placental chromosome.

Secondary Measures

  • Determine the proportion of chromosomal placental etiology in Intrauterine Growth Restriction.
    • Time Frame: Inclusion date
    • Proportion will be described in terms of percentage counts and 95% confidence interval depending on the test Fisher’s exact (p <0.05)

Participating in This Clinical Trial

Inclusion Criteria

  • over 18 years old, – treated in the DDIANE fetal medicine centre at the Bordeaux University Hospital, – having a fetus with IUGR diagnosis below the 3rd percentile (after reference medical ultrasound), – from 16 weeks of amenorrhea or more, – accepting an Invasive Prenatal Diagnosis by amniocentesis with array comparative genomic hybridization Exclusion Criteria:

Childbearing women who:

  • do not accept a non-invasive prenatal diagnosis (amniocentesis) – have a fetus with non-isolated IUGR (associated with other ultrasound signs) – do not consent to participate in the research protocol

Gender Eligibility: Female

having a fetus with IUGR diagnosis below the 3rd percentile (after reference medical ultrasound)

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • University Hospital, Bordeaux
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Caroline THAMBO, 05 56 79 59 52, caroline.rooryck-thambo@chu-bordeaux.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.